Patienter, der samtidig er inficeret med HCV/ HIV og som modtager peginterferon alfa- 2b/ ribavirin behandling og HAART kan have øget risiko for at udvikle hæmatologiske unormaliteter (som neutropeni, thrombocytopeni og anæmi) sammenlignet med HCV mono- inficerede patienter.
HCV/ HIV co-infected patients receiving peginterferon alfa-2b/ ribavirin treatment and HAART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.